Published in Vaccine Weekly, July 5th, 2000
"We have developed multiple inhibitory RNA-based strategies targeted to various steps of the HIV life cycle," reported Laurence Gagnon and colleagues from the Beckman Research Institute of City of Hope, California. "We have already demonstrated strong HIV inhibition by ribozymes, Rev or Tat binding aptamers, tRNAlys3-ribozyme chimeric RNAs, and anti-CCR5 ribozymes."
Cagnon et al. presented data from their study at the Keystone Symposium, "Novel Biological Approaches to HIV-1 Infection Based on New Insights into HIV Biology," held in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly